Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2002 Dec;236(6):806-13.
doi: 10.1097/00000658-200212000-00013.

Regional targeting chemoimmunotherapy in patients undergoing pancreatic resection in an advanced stage of their disease: a prospective randomized study

Nikolaos J Lygidakis  1 , George Sgourakis, Dedemadi Georgia, Lambros Vlachos, Sotirios Raptis
Affiliations
Clinical Trial

Regional targeting chemoimmunotherapy in patients undergoing pancreatic resection in an advanced stage of their disease: a prospective randomized study

Nikolaos J Lygidakis et al. Ann Surg. 2002 Dec.

Abstract

Purpose: To evaluate in a prospective randomized study the long-term results of adjuvant locoregional chemoimmunotherapy in a number of patients with stage III pancreatic duct cancer who underwent pancreatic resection between November 1993 and October 2000.

Methods: One hundred twenty-eight patients were divided into three groups. Group A (n = 40) patients had surgical resection alone. Group B (n = 45) patients had, using a side arterial branch of the jejunal artery, an arterial catheter advanced under fluoroscopic control into the superior mesenteric artery. Group B patients also received adjuvant chemotherapy. Group C (n = 43) patients had the same kind of arterial catheter and received as an adjuvant treatment locoregional chemoimmunotherapy. During the initial surgical exploration, all patients underwent pancreatic resection. Pancreatic resection involved a standard technique of extended duodenopancreatectomy with regional lymphadenectomy and was carried out in all patients by the first author. At the end of intervention, all patients were randomly assigned to the above-mentioned groups. Randomization was based mainly on histologic evidence of the stage of the disease.

Results: The 2- and 5-year survival rates were 29% and 0% for group A, 52% and 10% for group B, and 65% and 18% for group C. The respective percentages for disease-free survival were 20% and 0% for group A, 35% and 7% for group B, and 58% and 11% for group C. Since statistical differences among groups were observed from the second and third years, the study was interrupted early for ethical reasons.

Conclusions: When applied regionally, combined chemoimmunotherapy is simple, safe, and effective. This type of therapy offers substantial advantages in terms of prolonging overall survival and improving disease-free survival compared to surgical resection alone or to surgical resection and adjuvant regional chemotherapy.

PubMed Disclaimer

Figures

None
Figure 1. Catheter in the superior mesenteric artery.
None
Figure 2. Compression of the portal vein.
None
Figure 3. Compression of the superior mesenteric vein.
None
Figure 4. Cumulative proportion of survival (Kaplan-Meier) for patients of all three groups.
None
Figure 5. Cumulative proportion of progression-free survival (Kaplan-Meier) for patients of all three groups.
See this image and copyright information in PMC

Comment in

References

    1. Nitecki SS, Sarr MG, Colby TV, et al. Long-term survival after resection for ductal adenocarcinoma of the pancreas. Is it really improving? Ann Surg 1995; 221: 59–66. - PMC - PubMed
    1. Fuhrman GM, Leach SD, Staley CA, et al. Rationale for en bloc vein resection in the treatment of pancreatic adenocarcinoma adherent to the superior mesenteric-portal vein confluence. Pancreatic Tumor Study Group. Ann Surg 1996; 223: 154–162. - PMC - PubMed
    1. Yamaguchi K. Pancreatic carcinoma: Reappraisal of surgical experiences in one Japanese university hospital. Hepato-Gastroenterology 1999; 46: 3257–3262. - PubMed
    1. Nagakawa T, Nagamori M, Futakami F, et al. Results of extensive surgery for pancreatic carcinoma. Cancer 1996; 77: 640–645. - PubMed
    1. Lygidakis NJ, Vlachos L, Raptis S, et al. Consecutive re-explorations for final resection of initially unresectable pancreatic head carcinoma. Hepato-Gastroenterology 1999; 46: 2229–2239. - PubMed

MeSH terms